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Abstract
Published data describing the efficacy and safety of autologous stem-cell transplantation (autoSCT) in post-transplant
lymphoproliferative disorders (PTLD) is limited to case reports. This is a retrospective analysis of 21 patients reported to the
EBMT registry who received an autoSCT for PTLD post solid organ transplant (SOT). Median age at autoSCT was 47
(range: 22–71) years. The commonest SOTs were kidney (48%) and liver (24%). Commonest histologies included DLBCL-
type PTLD (14/21) and plasmacytoma-like PTLD (3/21). Patients received a median of two lines of therapy (range: 1–4) pre-
autoSCT. ECOG performance status pre-autoSCT was 0 in 14% and 1 in 86%. Remission status pre-autoSCT was CR 47%
and PR 38%. BEAM conditioning was used in 57% and high-dose melphalan in 10%. The median follow-up post-autoSCT
was 64 months for alive patients. 3-year PFS was 62% [95% confidence interval (CI) 44–87%] and 3-year OS was 61%
[95% CI:43–86]. There were 12 deaths, including four related to autoSCT. 100-day non-relapse-mortality (NRM) was 14%
and 1-year NRM was 24%. This study suggests that autoSCT, although feasible and with potential therapeutic activity, is
associated with a high NRM, primarily driven by infectious toxicity. A multi-disciplinary approach, expert microbiological
input and stringent patient selection are required to optimise outcomes.
Introduction
Post-transplant lymphoproliferative disorders (PTLD)
represent a clinical and histopathological spectrum of dis-
ease; from reactive to aggressive malignant phenomena
occurring typically in the setting of immunosuppression
associated with solid organ transplantation (SOT) [1].
Although PTLD can present with a variety of histological
subtypes, the most common form of PTLD has a CD20-
positive, B-cell monomorphic diffuse large B cell
lymphoma (DLBCL)-like histology. As a result of the
relative rarity of PTLD, large prospective clinical trials
which enable clear clinical treatment pathways have been
understandably scarce. Moreover, patients with PTLD have
historically been excluded from prospective clinical trials
studying novel therapies in aggressive B-cell lymphoma
due to the associated underlying immunosuppression,
impaired performance status (PS) at presentation and asso-
ciated organ dysfunction. To date, the only prospective
evidence to guide management is limited to phase II trials
[2, 3] in the front-line setting.
High-dose chemotherapy with autologous stem cell
transplantation (autoSCT) is considered the standard treat-
ment approach for patients with relapsing or refractory (R/
R) aggressive non-Hodgkin lymphoma and classical
Hodgkin lymphoma (cHL) [4–6]. Outcomes are well
described in these settings, with clear treatment pathways
and prognostic factors having been established. In contrast,
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there are no prospective or retrospective data to guide
decision making with regards to the potential utility and
safety of autoSCT in patients with R/R PTLD. The
evidence-based data is limited to a small number of case
reports across various histologies [7–9]. In patients unre-
sponsive to rituximab monotherapy, the safety and efficacy
of treatment with the combination of rituximab, cyclopho-
sphamide, doxorubicin, vincristine and prednisolone (R-
CHOP) has been demonstrated in prospective phase II trials
[2, 3, 10]. In a small case series from the pre-rituximab era,
9 patients with PTLD after SOT R/R after first-line CHOP
chemotherapy were treated with CE (carboplatin and eto-
poside). Five of 9 achieved durable complete remissions
without further treatment [11]. In patients that relapse fol-
lowing R-CHOP or who are refractory to this treatment,
conventional platinum-based salvage approaches followed
by consolidation with an autoSCT in chemotherapy
responsive patients akin to treatment used in DLBCL
[5, 12, 13] are sometimes employed with little evidence
base. Particular attention should be paid to the potential
toxicities of salvage chemotherapy [14] in relation to the
underlying SOT. The effect of salvage chemotherapy and
autoSCT on the function of the transplanted solid organ is
also poorly understood.
To begin to address these key unanswered questions, the
Lymphoma Working Party of the European Society for
Blood and Marrow Transplantation (EBMT) conducted a
retrospective study analysing the outcomes of patients with
PTLD following a SOT who received an autoSCT, either in
the front-line or relapsed setting, and were reported to the
EBMT registry. To our knowledge, this is the only series of
patients with PTLD treated with an autoSCT as consolida-
tion treatment for whom detailed toxicity, engraftment and
survival outcome is described.
Materials and methods
The EBMT is a voluntary organisation comprising more
than 600 transplant centres. Member centres submit at least
minimal essential data (Med-A form) from consecutive
patients to the lymphoma registry. We conducted an inter-
national, multicentre, retrospective EBMT registry study to
describe the characteristics and outcomes of patients ≥18
years of age with a known diagnosis of PTLD following a
SOT, for which they received an autoSCT at some point
(front-line or at relapse) between 2001 and 2017. Thirteen
transplant sites across the EBMT registry participated in this
study. All histological subtypes were included. Patients who
developed PTLD following allogenic SCT were excluded.
Transplant centres with potential patients were contacted to
obtain additional information (Med-B and Med-C forms).
Informed consent was obtained locally according to the
regulations applicable at the time of transplantation. After 1
January 2003, all EBMT centres have been required to
obtain written informed consent before data registration.
Remission status at autoSCT was defined according to
EBMT definitions: complete response (CR) was defined as
the disappearance of tumour masses and disease-related
symptoms; partial response (PR) was considered when
measurable lesions decreased by ≥50%. Relapse was
defined as the occurrence of new sites of disease following a
CR lasting for ≥3 months, whereas it was defined as pro-
gressive disease (PD) when CR had not been achieved.
Stable disease (SD) was defined as patients with neither CR,
PR or PD. Follow-up monitoring of patients for relapse/PD
post-transplant was conducted according to local centre
protocol. Overall survival (OS) was defined as the time
from autoSCT to death from any cause. Progression-free
survival (PFS) was defined as the time from autoSCT until
disease relapse/PD or death from any cause. Non-relapse
mortality (NRM) included all causes of death occurring
after autoSCT in the absence of relapse/PD. PFS and OS
were both estimated by the Kaplan–Meier method [15].
The primary endpoint of the study was PFS. Secondary
endpoints included OS, NRM, cumulative incidence of
relapse and engraftment. Additional information was collected
on management of immunosuppressive therapy pre- and post-
autoSCT, and transplanted organ function following
autoSCT. The patient characteristics that were collected
included age, gender, type and reasons for SOT. PTLD
characteristics collected included bulk disease (≥7.5 cm in any
diameter) at PTLD diagnosis and number and site of involved
extranodal sites. Epstein-Barr Virus (EBV) status and histo-
pathological PTLD subtype was assessed by clinician review
(TE) of written histopathology reports. EBV was considered
positive if expression was noted by either in situ hybridisation
for EBV‐encoded small RNA (EBER) or by Latent Mem-
brane Protein 1 expression by immunohistochemistry. Data
on the number of prior therapeutic lines, ECOG PS at
autoSCT, PTLD remission status at autoSCT, autoSCT con-
ditioning regimen and haematopoietic stem cell source were
also collected. Statistical analysis of baseline characteristics
was descriptive. Follow-up was censored at the most recent
medical visit or death. The database was locked on December
2019 for analysis.
Results
Twenty-one patients were included in the analysis. Patient
characteristics are summarised in Table 1 and PTLD char-
acteristics and treatment-related details are summarised in
Table 2. The median age of the cohort was 45 (range 21–70)
years at PTLD diagnosis and the median age at autoSCT
was 47 (range 22–71) years. 15 patients (71%) were female.
T. A. Eyre et al.
The reasons for the underlying SOT are listed in Table 3.
The most common type of SOT was kidney followed by
liver SOT. Four patients required a second SOT (renal n=
3; liver n= 1). Three of these SOTs were performed prior to
PTLD diagnosis and also therefore prior to autoSCT. One
patient with HELLP syndrome required an immediate sec-
ond liver SOT due to a non-functioning first liver SOT. A
second patient required a repeat kidney SOT following a
prior kidney-pancreas SOT for diabetes. A third patient with
endocardial fibroelastosis required a kidney SOT 20 years
after a previous heart SOT. A single patient with cystic
fibrosis received a lung SOT and developed chronic renal
failure following PTLD and the autoSCT and required a
kidney SOT 5 years post-autoSCT.
The median time from initial SOT to first diagnosis of
PTLD was 8.3 years (range 0.2–24). A variety of immu-
nosuppressive therapeutic approaches were used, consistent
with the timing, range of centres and SOT types studied.
Steroids, calcineurin inhibitors, azathioprine and myco-
phenolate combinations were typically used as immuno-
suppressive treatment pre and post autoSCT (Table SI).
Histological PTLD subtypes included monomorphic B-cell
DLBCL-type PTLD most commonly but also plasmacytoma-
like, T-cell lymphoma PTLD, and monomorphic B cell
Burkitt-type PTLD. EBV expression was evaluable in 17
patients. It was unknown or not tested the other 4 patients.
EBV expression was positive in 3 (18%) of these 17 patients
in whom their EBV tumour status was known. Expression in
these 3 patients was either by EBER in situ hybridisation
(n= 1) or LMP-1 immunohistochemistry (n= 2).
The median time from PTLD diagnosis to autoSCT was
14 months (4–89). Patients received a median of 2 treatment
Table 2 PTLD characteristics and treatment.
Number N (%) Number
available
Bulk at diagnosis, number (%)
Yes 5 (29%) 17
No 12 (71%)
Histological PTLD subtype, number (%) 21
Monomorphic B-cell DLBCL-type 14 (67%)
Plasmacytoma-like 3 (14%)
Monomorphic B-cell Burkitt type 1 (5%)
T-cell lymphoma 2 (10%)
Polymorphic B-cell PTLD with
plasmacytic differentiation
1 (5%)





>1 Extranodal site, number (%) 4 (21%) 19
Time from diagnosis to autoSCT months
[years (median, range)]
14 (4–89) 21
Number of lines of therapy before autoSCT
(median, range)
2 (1–4) 21
Number of lines of therapy before autoSCT, number (%)









Stem cell source, number (%) 21
PBSCH 100%
BM 0%
Conditioning regimen for autoSCT, number (%)







High Dose Melphalan 2 (10%)
Other 1 (5%)
autoSCT autologous stem cell transplantation, PTLD post-
transplantation lymphoproliferative disease, IPI international prognos-
tic index, PTCL peripheral T cell lymphoma, ECOG eastern co-
operative oncology group, PBSCH peripheral blood stem cell harvest,
BM bone marrow, BEAM carmustine, etoposide, cytarabine, melpha-
lan, LEAM lomustine, etoposide, cytarabine, melphalan, C cyclopho-
sphamide, R rituximab. *EBV status defined by LMP-1
immunohistochemistry or in situ hybridisation for EBV-encoded small
RNA (EBER).
aEBV status defined by LMP-1 immunohistochemistry or in situ
hybridisation for EBV-encoded small RNA (EBER).
Table 1 Baseline patient characteristics.





Age at first solid organ transplant
(SOT) [years (median, range)]
36 (4–55) 21
Time from SOT to diagnosis of
PTLD [years (range)]
8.3 (0.2–23.7) 21
Age at PTLD diagnosis [years
(median, range)]
45 (21–70) 21
Age at autoSCT [years (median,
range)]
47 (22–71) 21
Number of SOT, number (%) 21
1 17 (81%)
2 4 (19%)
Type of SOT, number (%)
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lines (range 1–4) prior to autoSCT. The timing of autoSCT
differed according to histological subtype. Patients with
monomorphic B-cell DLBCL-type PTLD received a median
of 2 (range 1–3) prior lines of therapy, patients with
plasmacytoma-like PTLD received a median of 1.5 (range
1–2) prior lines of therapy whereas patients with T-cell
lymphoma PTLD received a median of 2.5 (range 2–3)
prior lines pre-autoSCT. Remission status pre-autoSCT was
as follows: CR 47%, PR 38%, SD 10%, PD 5%.
The most commonly used autoSCT conditioning regi-
men was carmustine, etoposide, cytarabine and melphalan
(BEAM) followed by high dose melphalan. No patients
received total body irradiation conditioning. Haematopoie-
tic stem cell source was peripheral blood in all patients. Of
the 16 patients with available data, 9 (56%) did not stop
immunosuppression before autoSCT (1 relapsed and died,
5 died without relapse) and 7 (44%) patients did (1 relapsed,
3 died without relapse). Detailed data on post-autoSCT
manipulation of immunosuppression was not available.
Engraftment of neutrophils (defined as two consecutive
absolute neutrophil counts ≥0.5 × 10^9/L) occurred in all 21
patients at a median of 10.5 (range: 9–16) days (Fig. 1A).
Engraftment of platelets (defined as two consecutive
unsupported platelet counts ≥20 × 10^9/L and no transfu-
sion within 7 previous days) occurred in 17 of the 20
patients with data available with a median time of 13 (range
11–18) days.
The median follow-up post autoSCT was 64 months
(range 23–127) for alive patients. Overall there were 12
deaths (Table SII) including four patients whose death was
felt related to the autoSCT. One of these 4 deaths also
occurred in the context of concurrent progressive PTLD but
was definitely not due to PTLD. Infection, pulmonary dys-
function and multiorgan failure were predominant features in
across this 12 patient cohort. The median time from autoSCT
to death was 3 months (range, <1 month–9 months) for this
group, whereas it was 40 months (range, 0–176) for the
remaining 8 patients whose death was not attributed to
autoSCT. The latest three deaths recorded occurred at 13, 14
and 15 years post autoSCT respectively. The causes of death
in those three late events were unknown (n= 2) and infective
endocarditis (n= 1). The 100-day NRM was 14% and the 1-
year NRM was 24% (Fig. 1B). Table SIII summarises the 10
patients who died from non-relapse causes. Nine patients had
received a single SOT (kidney n= 5, liver n= 2, lung n= 1,
heart n= 1) and a single patient received a kidney-pancreas
and then a subsequent repeat kidney SOT2 8 years following
SOT1 - and 3 years prior to the autoSCT. The median time
from latest SOT to autoSCT was 8.7 years (range 1.8–14.0
years). 8 of 9 patients with available data restarted some form
of immunosuppression following the autoSCT.
Only 3 patients progressed (n= 1) or relapsed (n= 2)
following autoSCT. Two of them died, one at 9 months post
autoSCT of infection and another 25 months post- trans-
plant of unknown cause (following a relapse at 23 months).
Five patients (24%) received an autoSCT in the first line
setting. All patients received chemotherapy prior to
autoSCT (VCD n= 2, MATRix n= 1, Mega-CHOP n= 1
and R-CHOP n= 1) with no patients managed purely by
reduction in immunosuppression. Two patients were in
partial remission and three were in complete remission.
Three of them died at 8, 55 and 176 months after autoSCT
due to infection in the setting of progressive disease (PR1),
unknown cause (PR1) and endocarditis (CR1), respectively.
Two other patients obtaining CR1 were alive with no
relapse at 34 and 120 months respectively. The 3-year PFS
across the whole cohort was 62% [95% confidence interval
(CI) 44–87%] and the 3-year OS was 61% [95% CI 43–86]
(Fig. 1C–1D). At last follow-up when data were censored,
16 patients had a transplanted organ after the first SOT, 3
did not (all of which had a second SOT), and there were 2
patients for whom the functional status of the transplanted
was unknown.
Discussion
To the best of the authors knowledge, this EBMT case
series represents the largest experience of autoSCT as a
treatment modality for patients with PTLD. Until now, the
use of autoSCT in patients with PTLD was based primarily
on extrapolation of outcome data from the non-PTLD set-
ting and on a very limited number of isolated case reports.
Table 3 Reasons for solid organ transplantation.
Renal (n= 10)/Renal-Pancreas (n= 2)
Chronic glomerulonephritis (n= 4)
Diabetes-associated type 1 nephropathy (n= 2)
Vesiculo-ureteric reflux disease (n= 1)
Adult polycystic kidney disease (n= 1)
Uropathy not-otherwise specified (n= 1)
Renal failure not-otherwise specified (n= 1)
Multiple angiolipomas of the kidney in tuberous sclerosis (n= 1)
Focal segmental glomerulosclerosis (n= 1)
Liver (n= 5)
Acute steatosis, HELLP (n= 1)
Cirrhosis (Hepatitis C) (n= 2)
Cirrhosis (alcoholic liver disease) (n= 1)
Cirrhosis (alcohol and hepatitis C) (n= 1)
Other: lung (n= 2), cardiac (n= 2)
Cystic fibrosis (n= 2)
Congenital Cardiomyopathy Secondary to Endocardial
Fibroelastosis (n= 1)
Not documented (n= 1)
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Whilst the survival outcomes require cautious inter-
pretation in light of the small and heterogenous population
evaluated, autoSCT as a consolidation strategy provided
durable disease control in the majority of patients within
this series, as only three relapses were recorded. We also
demonstrate that this approach led to a 100-day NRM of
14% and a 1-year NRM of 24%. The toxicity associated
with autoSCT in the setting of PTLD is considerably higher
than the 2–5% range described post autoSCT in the setting
of cHL [16], T cell lymphoma [17] or aggressive B-cell
lymphoma [18, 19] in patients without a SOT and asso-
ciated immunosuppression. This concerning finding is per-
haps unsurprising but has never been previously
demonstrated in the literature and has to be considered in
the context of survivorship after SOT, with a 5-year survival
ranging from around 50% for lung recipients to more than
90% for renal recipients. Evaluation of risk factors for
infection such as dosing of co-existing immunosuppression,
myelotoxicity of autoSCT conditioning, and pre-existent
organ dysfunction should therefore be extremely carefully
assessed when autoSCT in patients with PTLD is con-
sidered. The importance careful patient selection and of
diligent multi-disciplinary communication including hae-
matologists, physicians/surgeons managing the underlying
SOT and microbiologists when managing toxicities here
cannot be understated.
Our study has several limitations to acknowledge, which
are inherent to the retrospective registry-based nature of the
study, and the heterogeneity of types and treating centres in
this small cohort. By definition, only patients from centres
reporting to the EBMT and only cases recorded as PTLD
were included. We cannot exclude the possibility that other
patients have received an autoSCT for PTLD in Europe and
have not been reported to the EBMT. The inherent diffi-
culties of a registry study to deal with missing data also
apply to this study. Both the baseline demographics (med-
ian age < 50 years, female predominance) and PTLD
characteristics (rate of EBV-association 18%) of our patient
cohort are unusual compared to previous trials and retro-
spective cohorts [2, 3, 20, 21], suggesting patient selection.
Given the heterogeneous histological subtypes and the
variable timing of autoSCT across the patients, it is chal-
lenging to provide generalizable recommendations. We also
were not able to analyse in detail the function of the SOT
pre or post autoSCT, but recognise this is of clinical rele-
vance. Finally, as only patients who actually received an
autoSCT are included in this study it is not possible to draw
strong conclusions on the role of this approach in compar-
ison with other strategies in the management of patients
with PTLD, particularly as the denominator for those the-
oretically eligible for autoSCT is unknown.
An additional noteworthy finding following this EBMT
project was the paucity of cases available for analysis. To
overcome the possibility that other patients with PTLD have
received an autoSCT in Europe and have not been reported
to the EBMT registry, we contacted two European PTLD
registries to ensure that we were not missing a significant
number of patients. Ongoing collaborative efforts are
required to ensure that patients with PTLD receiving
































































































































































































Fig. 1 Survival, Relapse and Engraftment for PTLD autoSCT
patients. A Cumulative incidence of neutrophil engraftment.
B Cumulative incidence of relapse and death without relapse.
C Progression-free survival with 95% confidence intervals. D Overall
survival with 95% confidence intervals.
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international registries. This will in turn enable considerably
larger patient numbers to be studied over time in order to
gain a greater understanding of more definitive survival,
toxicity and prognostic factors.
In conclusion, we present outcomes of patients with
PTLD treated with an autoSCT within the EBMT registry
over the past two decades. We demonstrate that autoSCT,
although feasible and with some evidence of therapeutic
activity, is a significantly toxic procedure and a stringent
selection of patients is necessary before recommending it.
As such, multi-disciplinary team based patient care, expert
microbiological input and careful patient selection are of
utmost importance to optimise long term disease control and
minimise toxicity. Ongoing international collaborative
efforts are required to further the evidence in this field as
well as the need for prospective international clinical trials.
Acknowledgements TE, JK, SR and SM contributed towards the
conception, design and conduct of the research. All authors other than
SM, SR, HT and AB performed data extraction from treating sites. TE
and SM wrote the final paper, which all authors read and approved
prior to submission.
Funding There was no funding from external agencies or pharma-
ceutical companies to support this study. TE recognises support from
the Oxford NIHR Biomedical Research Centre.
Compliance with ethical standards
Conflict of interest Dr HZ reports institutional grants from Atara and
Roche and travel support from Atara, Celgene, and Jansen, outside the
submitted work. Dr RUT reports institutional grants from Atara and
Roche and non-financial support from Roche, Atara, Celgene, Janssen
and AbbVie, all outside the submitted work. All other authors have
declared no relevant competing interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of
post-transplant lymphoproliferative disorders. Br J Haematol.
2018;182:330–43.
2. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P,
et al. Sequential treatment with rituximab followed by CHOP
chemotherapy in adult B-cell post-transplant lymphoproliferative
disorder (PTLD): the prospective international multicentre phase 2
PTLD-1 trial. Lancet Oncol. 2012;2:196–206.
3. Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee
P, Zaucha JM, et al. Response to rituximab induction is a pre-
dictive marker in B-cell post-transplant lymphoproliferative dis-
order and allows successful stratification into rituximab or r-chop
consolidation in an international, prospective, multicenter Phase II
trial. J Clin Oncol. 2017;5:536–43.
4. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel
M, et al. Aggressive conventional chemotherapy compared with
high-dose chemotherapy with autologous haemopoietic stem-cell
transplantation for relapsed chemosensitive Hodgkin’s disease: a
randomised trial. Lancet. 2002;359:2065–71.
5. Van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna
KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage
chemoimmunotherapy in relapsed or refractory diffuse large B-cell
lymphoma: The ORCHARRD study. J Clin Oncol. 2017;5:544–51.
6. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC,
Trneny M, et al. Salvage regimens with autologous transplantation
for relapsed large B-cell lymphoma in the rituximab era. J Clin
Oncol. 2010;28:4184–90.
7. Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN. Mini-
BEAM and autologous hematopoietic stem-cell transplant for
treatment of post-transplant lymphoproliferative disorders. Am J
Hematol. 2005;3:211–5.
8. Bobey NAM, Stewart DA, Woodman RC. Successful treatment of
posttransplant lymphoproliferative disorder in a renal transplant
patient by autologous peripheral blood stem cell transplantation.
Leuk Lymphoma. 2002;12:2421–2413.
9. Malhotra B, Rahal AK, Farhoud H, Moore Jr DF, Kallail KJ.
Treatment of Recurrent Posttransplant Lymphoproliferative Disorder
with Autologous Blood Stem Cell Transplant. Case Rep Transplant.
2015;2015:801082. https://doi.org/10.1155/2015/801082.
10. Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S,
et al. Salvage chemotherapy for refractory and relapsed post-
transplant lymphoproliferative disorders (PTLD) after treatment
with single-agent rituximab. Transplantation. 2007;12:1708–12.
11. Oertel SH, Papp-Váry M, Anagnostopoulos I, Hummel MW,
Jonas S, Riess HB. Salvage chemotherapy for refractory or
relapsed post-transplant lymphoproliferative disorder in patients
after solid organ transplantation with a combination of carboplatin
and etoposide. Br J Haematol. 2003;5:830–5.
12. Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M
et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse
large B-cell lymphoma (DLBCL) followed by autologous stem cell
transplantation: CORAL study. J Clin Oncol. 2009;27:8509-8509.
https://doi.org/10.1200/jco.2009.27.15_suppl.8509.
13. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V,
Kouroukis CT, et al. Randomized comparison of gemcitabine,
dexamethasone, and cisplatin versus dexamethasone, cytarabine,
and cisplatin chemotherapy before autologous stem-cell trans-
plantation for relapsed and refractory aggressive lymphomas:
NCIC-CTG LY.12. J Clin Oncol. 2014;31:3490–6.
14. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum
CD. Long-term renal outcomes after cisplatin treatment. Clin J
Am Soc Nephrol. 2016;7:1173–9.
15. Bland JM, Altman DG. Statistics Notes: survival probabilities (the
Kaplan-Meier method). BMJ. 1998;317:1572–80.
16. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB,
Slungaard A, et al. Long-term results of autologous stem cell
transplantation for primary refractory or relapsed Hodgkin’s
lymphoma. Biol Blood Marrow Transpl. 2006;10:1065–72.
T. A. Eyre et al.
17. D’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H,
Anderson H, et al. Up-front autologous stem-cell transplantation
in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;
25:3093–9.
18. Robinson SP, Boumendil A, Finel H, Blaise D, Poiré X,
Nicolas-Virelizier E, et al. Autologous stem cell transplan-
tation for relapsed/refractory diffuse large B-cell lymphoma:
efficacy in the rituximab era and comparison to first
allogeneic transplants. A report from the EBMT
Lymphoma Working Party. Bone Marrow Transpl. 2016;51:
365–71.
19. Robinson SP, Boumendil A, Finel H, Dreger P, Sureda A, Her-
mine O, et al. High-dose therapy with BEAC conditioning com-
pared to BEAM conditioning prior to autologous stem cell
transplantation for non-Hodgkin lymphoma: no differences in
toxicity or outcome. A matched-control study of the EBMT-
Lymphoma Working Party. Bone Marrow Transpl. 2018;12:
1553–9.
20. González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-
Codina J, Salar A, Bauen A, et al. Prospective phase II trial of
extended treatment with rituximab in patients with B-cell post-
transplant lymphoproliferative disease. Haematologica. 2007;
11:1489–94.
21. Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A,
et al. Post-transplantation lymphoproliferative disorder after kid-
ney transplantation: Report of a nationwide French registry and
the development of a new prognostic score. J Clin Oncol.
2013;10:1302–9.
Affiliations
Toby A. Eyre 1 ● Sophie Caillard2 ● Herve Finel3 ● Ariane Boumendil3 ● Jaimal Kothari1 ● Heiner Zimmermann4 ●
Ralf Ulrich Trappe4,5,6 ● Virginie De Wilde7 ● Eleni Tholouli8 ● Edward Kanfer9 ● Angus Broom10 ● Gandhi Damaj 11 ●
Mario Bargetzi12 ● Tomáš Kozák13 ● Inken Hilgendorf 14 ● Charles Crawley15 ● Tessa Kerre16 ● Marek Trněný13 ●
Emmanuel Bachy17 ● Stephen Robinson3,18 ● Silvia Montoto3,19
1 Department of Haematology, Cancer and Haematology Centre,
Churchill Hospital, Oxford University Hospitals NHS Foundation
Trust, Oxford, UK
2 Nephrology Transplantation Department, Strasbourg University
Hospitals, Strasbourg, France
3 Lymphoma Working Party EBMT, Paris, France
4 Department of Hematology and Oncology, DIAKO Ev. Diakonie-
Krankenhaus Bremen, Bremen, Germany
5 Department of Internal Medicine II: Hematology and Oncology,
University Medical Centre Schleswig-Holstein, Campus Kiel,
Kiel, Germany
6 Department of Hematology and Oncology, Charité-
Universitätsmedizin Berlin, Berlin, Germany
7 Erasmus Hospital, Route de Lennik 808, 1070 Bruxelles, Belgium
8 Manchester Royal Infirmary, Oxford Road, Manchester, UK
9 Department of Haematology, Hammersmith Hospital,
London, UK
10 Department of Haematology, Western General Hospital,
Edinburgh, UK
11 Department of Haematology, Hospital Center University of Caen,
Caen, Normandy, France
12 Department of Haematology, Kantonsspital, Aarau, Switzerland
13 Department of Haematology, Charles University Hospital,
Prague, Czech Republic
14 Department of Haematology, Jena University Hospital,
Jena, Germany
15 Department of Haematology, Addenbrookes Hospital,
Cambridge, UK
16 Department of Haematology, Ghent University Hospital,
Ghent, Belgium
17 Department of Haematology, Hospices Civils, Lyon, France
18 BMT Unit, University Hospital Bristol NHS Foundation Trust,
Bristol, UK
19 Department of Haemato-oncology, St Bartholomew’s Hospital,
Barts Health NHS Trust, London, UK
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid. . .
